{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6Yo8UKDA","lastupdate":"2021-04-18T00:00:00.000Z","update_date":"2021-04-18T00:00:00.000Z","lastModified":"Sep 7, 2024","active":1,"confidence_score":89,"confidence_score_reason":"funding rounds, markets, not claimed","urlname":"hervana","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$flUu3FUWw5ZrhDShgIsBNHT2pignyAcCBGCr0yoErz0qga4kkExVUa","name":"Hervana Bio","oneliner":"Non-hormonal Female Contraceptive Technology Offering Protection Against STIs","registrar":"514154038","website":"https://hervana-bio.com","careerspage":"","founded_month":6,"founded_year":2008,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/2090562","instagram":""},"social":["https://www.linkedin.com/company/2090562"],"flattenedsociallinks":"https://www.linkedin.com/company/2090562","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"1-10","employees_exact":2,"patent":1,"raised":1100000,"stage":"Pre-Funding","public_stage":"Pre-Funding","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["HervanaBio","Hervana"],"about":"Hervana Bio is a biopharmaceutical company that develops womens health products. The company has developed a female contraceptive platform technology that is non-hormonal and offers protection against sexually transmitted infections.\r\n\r\nHervanas LJ-102 is a highly effective, long-lasting contraceptive technology free from the drawbacks of current hormone-based contraceptives. The products safety profile and prolonged action enable greater compliance and accessibility, particularly in populations where the available methods of contraception are contraindicated, undesirable, or socially unacceptable.\r\n\r\nIn 2012, Hervana Bio received a $1 million grant from the Bill and Melinda Gates Foundation.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"","country":null,"address":{"israeli":[{"id":"335a9b8c-4147-44dc-958f-aa9da4878736","city":"Jerusalem","type":null,"address":"Naftali Street 9, Jerusalem, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Jerusalem District","news":[{"id":"GfIstHaCk3iJH1ioD80r5UYF2MlL2AnpGwstlHcuLbZ6YOvgKeSMoX","date":"Apr 3, 2024","link":"https://www.calcalistech.com/ctechnews/article/kq31zta9k","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"Healthcare, Contraception","company":"Hervana Bio","layoffs":"Not mentioned","summary":"Hervana Bio, a biopharmaceutical company, is developing a non-hormonal contraceptive with added protection against sexually transmitted infections (STIs). The contraceptive is based on lactobacilli, a bacteria found in the female reproductive tract, and is currently in the trial stage with a reported 100% efficacy rate. The contraceptive also has the potential to prevent STIs. The company is seeking additional funding to further develop and market the product. The contraceptive market is valued at $20 billion and is expected to reach $25 billion by 2027.","partners":"Not mentioned","customers":"Not mentioned","investors":["Bill and Melinda Gates Foundation"],"confidence":9,"key_topics":["Non-hormonal Contraceptive","STI Protection","Funding","Womens Health","Market Potential"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Nb8he01saNskzDy2EXslZyX5ZrzJLPezatsWnJusTup6mczvualXrS","news_summary":"The Israeli startup developing the first new, non-hormonal contraceptive in 60 years | CTech","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"d85b96a8-a0d2-4fcd-8890-e01c15b51faa","date":"Jan 31, 2018","link":"http://www.prweb.com/releases/2018/01/prweb15132007.htm","source":"www.prweb.com","visible":1,"analysis":{"tags":"Contraceptive Technology","company":"Hervana Bio","layoffs":"Not mentioned","summary":"Hervana Bios CEO, Rachel Teitelbaum, has presented an update on the development of HER-102, a reversible female contraceptive, at the Microbiome Drug Development Summit Europe. The contraceptive harnesses the power of antibodies to prevent pregnancy and protect against sexually transmitted infections, including HIV. The contraceptive effect has been shown to be fully reversible, with no negative effects in preliminary toxicology studies. Hervana Bio is an Israeli-based biopharmaceutical company dedicated to innovating products in womens health.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":8,"key_topics":["HER-102","Contraceptive","Vaginal Microbiome","Disease Prevention","Sexually Transmitted Infections"],"date_of_event":"January 31, 2018","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"12XLaxzrkRx9JiJNIdxhV2PKotStT8w1tFRjniAVWthsfXHQP5mbFz","news_summary":"Hervana Bio Founder and CEO Dr. Rachel Teitelbaum Provides Update on Female Contraceptive Development at Microbiome EU Summit","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"2d94e4b8-e2ca-4aa0-af21-220565ba6e3e","date":"Dec 28, 2012","link":"http://www.bioisrael.com/bill-gates-grants-hervana-1m-for-contraceptive","source":"www.bioisrael.com","visible":1,"analysis":{"tags":"contraceptive technology","company":"Hervana","layoffs":null,"summary":"Hervana has been awarded a $1 million grant from the Bill & Melinda Gates Foundation for the development of a long-acting, non-hormonal contraceptive platform technology. The grant will support the creation of a vaginal suppository that only needs to be applied once or twice a month, providing a low-cost and non-invasive contraceptive option. The CEO and founder of Hervana, Rachel Teitelbaum, highlights the need for a contraceptive free of health risks and medical procedures, especially in developing countries where there is a lack of accessible options. The Gates Foundation is excited about this application for the developing world, as there are over 220 million women without access to effective contraception and 50 million abortions per year in the developing world.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["contraceptive technology","non-hormonal","developing countries","accessibility","Gates Foundation"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"XJFCNaX9qSUSmhjSCCyNQ4br1FziRIYEKmVQVEyEmva4RF903lHjhS","news_summary":"Bill Gates Grants Hervana $1M for Contraceptive","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":3,"techcommunityinvolvement":null,"mediagallery":[{"id":"9edfacdf-52eb-43d4-b15a-b252bf111967","timestamp":"2016-06-16 12:32:37.000000","resources_type":1,"resources_title":"Probiotic therapy","resources_file_name":"$CVcNMbro9GK1hZmZwHl1GdVXX68O900fmfq7Z98FpOUTCGersYi5Zv","alt":"Probiotic therapy logo","cleanBucketUrl":"https://storage.googleapis.com/clean-finder-353810","imageurl":"https://storage.googleapis.com/clean-finder-353810/$CVcNMbro9GK1hZmZwHl1GdVXX68O900fmfq7Z98FpOUTCGersYi5Zv","url":"https://storage.googleapis.com/clean-finder-353810/$CVcNMbro9GK1hZmZwHl1GdVXX68O900fmfq7Z98FpOUTCGersYi5Zv"}],"tags":["pregnancy","biotechnology","women-health","pharmaceuticals","women","femtech"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rOELDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B","B2B2C"],"productstage":"Clinical Trial","products":[],"geomarkets":["United States"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":0,"lastfunding":"$1M","totalrounds":2,"fundingstage":"Pre-Funding","totalfunding":"$1.1M","publicinvestors":0,"lastpublicfunding":1000000,"totalpublicrounds":2,"totalpublicfunding":1100000},"team":[{"name":"Rachel Teitelbaum, PhD","email":"rteitlbaum@hervana-bio.com","phone":"0528715250","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgN7Qzo4IDA","bounced":false,"claimed":0,"founder":1,"urlname":"rachel-teitelbaum-phd","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICAsd-S3AkM","position":"Founder & CEO","last_name":"Teitelbaum, PhD","claimtoken":"2cfdb82dff2fb0b5cb757cbc71c742e0fdedec7ad72e67c0fe8360ae27820f72","first_name":"Rachel","picturekey":"$AJnCLjLN1tDiNTODuNg0DqmRsPNkfOclNDFUBxOWP57MmeZs2c84Hw","claimeddate":null,"linkedinurl":"https://www.linkedin.com/pub/rachel-teitelbaum-ph-d/3/b85/89a","unsubscribed":false,"is_activeuser":1,"additionalemail":"rt_hervana@yahoo.com","claimedemaildate":"2021-04-13 11:06:17.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$AJnCLjLN1tDiNTODuNg0DqmRsPNkfOclNDFUBxOWP57MmeZs2c84Hw","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgLHD0KwIDA","fullname":"Sharon Shapira"},"biverifydate":"2020-03-19T00:00:00.000Z","crunchbaseid":"hervana","lastupdator":"Paul Weisko","lastupdator_email":"pweisko@gmail.com","creator":"Arielle Smolin","creator_email":"ari.smolin@gmail.com","createdate":"2014-07-16T00:00:00.000Z","biverification":"Sharon Shapira","sectorverification":"Natalia Golczar","affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEzeaYCgw","date":"Dec 2012","amount":"$1M","source":"Added by Daniela Gehtaman","eventtype":"GrantEvent","granttype":0,"investment":[{"name":"Bill & Melinda Gates Foundation","type":"Other","amount":0,"hidden":false,"country":"United States","fullurl":"/company_page/bill-melinda-gates-foundation","logokey":"$s5vSxtfqh4JvoW6IVECOCOfFO9gs9XP0cj6tRo4neNrU1fTUkZ7Et7","tagline":"","urlname":"/company_page/bill-melinda-gates-foundation","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODEu8reCAw","fundingtype":"Other","leadpartner":null,"investmentid":"3cffb201-c71a-4e86-bd50-6cb5be3cdfa4","fundingsubtype":"","investorislead":null,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$s5vSxtfqh4JvoW6IVECOCOfFO9gs9XP0cj6tRo4neNrU1fTUkZ7Et7","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":1000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOD9-d6GCgw","date":"May 2010","amount":"$100K","source":"https://www.globes.co.il/news/article.aspx?did=1000558957","eventtype":"GrantEvent","granttype":0,"investment":[{"name":"Bill & Melinda Gates Foundation","type":"Other","amount":0,"hidden":false,"country":"United States","fullurl":"/company_page/bill-melinda-gates-foundation","logokey":"$s5vSxtfqh4JvoW6IVECOCOfFO9gs9XP0cj6tRo4neNrU1fTUkZ7Et7","tagline":"","urlname":"/company_page/bill-melinda-gates-foundation","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODEu8reCAw","fundingtype":"Other","leadpartner":null,"investmentid":"a8eb1f64-7dc4-4fe6-8f7b-16c435487f3e","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$s5vSxtfqh4JvoW6IVECOCOfFO9gs9XP0cj6tRo4neNrU1fTUkZ7Et7","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":100000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"6/2008","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Hervana Bio","logourl":"https://storage.googleapis.com/clean-finder-353810/$flUu3FUWw5ZrhDShgIsBNHT2pignyAcCBGCr0yoErz0qga4kkExVUa","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$flUu3FUWw5ZrhDShgIsBNHT2pignyAcCBGCr0yoErz0qga4kkExVUa","seoabout":"Hervana Bio is a biopharmaceutical company that develops womens health products. The company has developed a female contraceptive platform technology that ...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":1,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Consumers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Demographics & Family","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Women","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rOELDA","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA>Demographics & Family#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA","IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA>Demographics & Family#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA>Women#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rOELDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA|2:>IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA/Demographics & Family#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA|3:>IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA>Demographics & Family#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA/Women#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rOELDA|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Consumers","key":"0-0","path":"IndustryClassificationModel>Consumers","children":[{"title":"Demographics & Family","key":"0-0-0","path":"IndustryClassificationModel>Consumers>Demographics & Family","children":[{"title":"Women","key":"0-0-0-0","path":"IndustryClassificationModel>Consumers>Demographics & Family>Women"}]}]},{"title":"Healthcare & Life Sciences","key":"0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-1-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-1-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals"}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Consumers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Demographics & Family","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Women","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rOELDA","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals"],"targetCustomer":["Consumers","Demographics & Family","Women","Healthcare & Life Sciences","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[],"nonequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEzeaYCgw","date":"Dec 2012","amount":"$1M","source":"Added by Daniela Gehtaman","eventtype":"GrantEvent","granttype":0,"investment":[{"name":"Bill & Melinda Gates Foundation","type":"Other","amount":0,"hidden":false,"country":"United States","fullurl":"/company_page/bill-melinda-gates-foundation","logokey":"$s5vSxtfqh4JvoW6IVECOCOfFO9gs9XP0cj6tRo4neNrU1fTUkZ7Et7","tagline":"","urlname":"/company_page/bill-melinda-gates-foundation","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODEu8reCAw","fundingtype":"Other","leadpartner":null,"investmentid":"3cffb201-c71a-4e86-bd50-6cb5be3cdfa4","fundingsubtype":"","investorislead":null,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$s5vSxtfqh4JvoW6IVECOCOfFO9gs9XP0cj6tRo4neNrU1fTUkZ7Et7","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":1000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOD9-d6GCgw","date":"May 2010","amount":"$100K","source":"https://www.globes.co.il/news/article.aspx?did=1000558957","eventtype":"GrantEvent","granttype":0,"investment":[{"name":"Bill & Melinda Gates Foundation","type":"Other","amount":0,"hidden":false,"country":"United States","fullurl":"/company_page/bill-melinda-gates-foundation","logokey":"$s5vSxtfqh4JvoW6IVECOCOfFO9gs9XP0cj6tRo4neNrU1fTUkZ7Et7","tagline":"","urlname":"/company_page/bill-melinda-gates-foundation","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODEu8reCAw","fundingtype":"Other","leadpartner":null,"investmentid":"a8eb1f64-7dc4-4fe6-8f7b-16c435487f3e","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$s5vSxtfqh4JvoW6IVECOCOfFO9gs9XP0cj6tRo4neNrU1fTUkZ7Et7","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":100000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"merger_acquisitions":[],"others":[]}}